The number of people given a prescription for tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) in the United States has grown steadily over the past several years, with 49 469 individuals prescribed the regimen between January 2013 and December 2015 alone, according to a study presented at the International AIDS Conference, AIDS 2016, in Durban, South Africa. 

The number of prescriptions increased over time, from 3746 in 2013 to 14 756 in 2014 and 30 967 in 2015, with significant gains noted in California, New York, Texas, and Florida, accounting for 43% of new PrEP prescriptions.

A majority of PrEP prescriptions were for men (87.5%), and the mean age was 37.4 years, with 11.5% under 25 years of age, according to data presented at the meeting from Gilead Sciences.1


Continue Reading

The authors noted that PrEP use must increase to ensure that lifetime HIV risk decreases in high-prevalence areas of the United States.

“Just as the 2000 International AIDS Conference in Durban ushered in a global movement to bring life-saving HIV treatment to the developing world, I am confident we’ll look back at this conference as the dawn of the global PrEP era,” Linda-Gail Bekker, MBChB, PhD, president-elect of the International AIDS Society and principal investigator at the Desmond Tutu HIV Centre, said in a press release about this study and other related studies.2 “A primary focus of this conference is moving science into practice, and nowhere is that need more urgent than for PrEP.” 

Reference

1. Mera R, McCallister S, Palmer B, et al. Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013-2015).

2.  IAS media. New research marks important step forward in understanding real-world use of PrEP. Both Presented at: 21st International AIDS Conference 2016; July 18-22, 2016; Durban, South Africa.